aTYR PHARMA (ATYR) Other financing activities (2015 - 2025)

aTYR PHARMA's (ATYR) quarterly Other financing activities came in at $17000.0 in Q2 2025, up 750.0% quarter-over-quarter from $2000.0 in Q1 2025.

Analysis

aTYR PHARMA (ATYR) Other financing activities (2015 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has reported Other financing activities for 7 consecutive years, with $17000.0 the latest figure, recorded in Q2 2025.

For the quarter ending Q2 2025, Other financing activities changed N/A year-over-year to $17000.0; the trailing twelve-month figure through Mar 2026 stood at $17000.0 (up 750.0% YoY), and the FY2025 full-year result was $19000.0, changed N/A from the prior year.
Other financing activities climbed to $17000.0 in Q2 2025 per ATYR's latest filing, from $2000.0 in the prior quarter.
Across five years, Other financing activities topped out at $58000.0 in Q3 2021 and bottomed at $1000.0 in Q1 2022.
Historically, Other financing activities has averaged $16200.0 across 3 years, with a median of $3000.0 in 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	208.48 Bn	194.49 Bn	7.24 Bn
2	Gilead Sciences	186.29 Bn	183.02 Bn	6.22 Bn
3	Vertex Pharmaceuticals	128.79 Bn	120.93 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	80.66 Bn	72.67 Bn	3.93 Bn
5	Moderna	61.46 Bn	56.32 Bn	52.00 Mn
6	Argenx Se	61.28 Bn	56.10 Bn	1.37 Bn
7	Alnylam Pharmaceuticals	32.04 Bn	28.73 Bn	992.69 Mn
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn
9	Roivant Sciences	28.74 Bn	29.43 Bn	1.16 Mn
10	aTYR PHARMA	35.31 Mn	-22.30 Mn	-

Historic Data

Download Data